Skip to main content

Table 3 Association of intensity of p53 overexpression with various clinical & pathological parameters

From: Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer

  n (%) P-Value
Weak (n = 21) Intermediate (n = 26) Strong (n = 57) Negative (n = 46) Total (n = 150)
Age groups
  ≤ 30 years 0 (0) 0 (0) 3 (5.3) 2 (4.3) 5 (3.3) 0.347
 31–50 years 8 (38.1) 14 (53.8) 34(59.6) 28 (60.9) 84 (56)
  > 50 years 13 (61.9) 12 (46.2) 20 (35.1) 16 (34.8) 61 (40.7)
Tumor stage/tumor size
 T1 (≤2 cm) 6 (28.6) 5 (19.2) 14 (24.6) 1 (2.2) 26 (17.3) 0.023
 T2 (2.1–5.0 cm) 9 (42.9) 12 (46.2) 29 (50.9) 29 (63) 79 (52.7)
 T3 (> 5.0 cm) 6 (28.6) 9 (34.6) 14 (24.6) 16 (34.8) 45 (30)
ki67 index groups
  ≤ 15% 5 (23.8) 8 (30.8) 1 (1.8) 3 (6.5) 17 (11.3) 0.006
 16–24% 1 (4.8) 2 (7.7) 3 (5.3) 2 (4.3) 8 (5.3)
 25–44% 7 (33.3) 7 (26.9) 16 (28.1) 15 (32.6) 45 (30)
  > 44% 8 (38.1) 9 (34.6) 37 (64.9) 26 (56.5) 80 (53.3)
Nodal Status
 Positive 9 (42.9) 13 (50) 21 (36.8) 21 (45.7) 64 (42.7) 0.675
 Negative 12 (57.1) 13 (50) 36 (63.2) 25 (54.3) 86 (57.3)
Nodal Stage
 No 12 (57.1) 13 (50) 36 (63.2) 27 (58.7) 88 (58.7) 0.357
 N1 5 (23.8) 7 (26.9) 8 (14) 10 (21.7) 30 (20)
 N2 0 (0) 5 (19.2) 5 (8.8) 3 (6.5) 13 (8.7)
 N3 4 (19) 1 (3.8) 8 (14) 6 (13) 19 (12.7)
Histological Subtypes
 IDC 17 (81) 21 (80.8) 50 (87.7) 39 (84.8) 127 (84.7) 0.620
 Papillary 1 (4.8) 1 (3.8) 3 (5.3) 1 (2.2) 6 (4)
 Medullary 0 (0) 1 (3.8) 0 (0) 0 (0) 1 (0.7)
 metaplastic 2 (9.5) 3 (11.5) 3 (5.3) 6 (13) 14 (9.3)
 Mixed 1 (4.8) 0 (0) 1 (1.8) 0 (0) 2 (1.3)
Tumor Grade
 Grade-I 1 (4.8) 0 (0) 0 (0) 0 (0) 1 (0.7) 0.041
 Grade-II 6 (28.6) 4 (15.4) 6 (10.5) 3 (6.5) 19 (12.7)
 Grade-III 14 (66.7) 22 (84.6) 51 (89.6) 43 (93.5) 130 (86.7)
Lymhovascular Invasion
 Present 7 (33.3) 6 (23.1) 15 (26.3) 8 (17.4) 36 (24) 0.516
 Absent 14 (66.7) 20 (76.9) 42 (73.7) 38 (82.6) 114 (76)
Perinodal extension
 Present 5 (23.8) 3 (11.5) 15 (26.3) 7 (15.2) 30 (20) 0.352
 Absent 16 (76.2) 23 (88.5) 42 (73.7) 39 (84.8) 120 (80)
Triple Negative phenotype
 Basal 3 (14.3) 3 (11.5) 5 (8.8) 5 (10.9) 16 (10.7) 0.913
 Non Basal 18 (85.7) 23 (88.5) 52 (91.2) 41 (89.1) 89.3)
  1. Chi-Square test applied
  2. P-value≤0.05 considered as significant
\